Pacer Advisors Inc. Buys 2,866 Shares of Sotera Health (NASDAQ:SHC)

Pacer Advisors Inc. grew its stake in shares of Sotera Health (NASDAQ:SHC) by 9.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 34,773 shares of the company’s stock after acquiring an additional 2,866 shares during the period. Pacer Advisors Inc.’s holdings in Sotera Health were worth $476,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SHC. Blue Trust Inc. lifted its holdings in Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after acquiring an additional 1,140 shares during the period. True Wealth Design LLC bought a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC boosted its holdings in shares of Sotera Health by 125.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares during the period. Capital Performance Advisors LLP purchased a new stake in Sotera Health during the 3rd quarter valued at $91,000. Finally, SG Americas Securities LLC bought a new position in Sotera Health during the third quarter valued at $163,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Performance

Sotera Health stock opened at $13.81 on Wednesday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market capitalization of $3.91 billion, a PE ratio of 55.24 and a beta of 1.92. The company has a 50 day moving average price of $13.32 and a 200-day moving average price of $14.57. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. As a group, equities analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Wall Street Analyst Weigh In

SHC has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. Citigroup upped their target price on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on Sotera Health in a research note on Friday, December 6th. They set a “neutral” rating and a $14.00 price target for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.